Mode of action of the monobactam LYS228 and mechanisms decreasing in vitro susceptibility in Escherichia coli and klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 10, 2018, Pages

  Dean, Charles R ^a   Barkan, David T ^a   Bermingham, Alun ^a   Blais, Johanne ^a   Casey, Fergal ^a,b   Casarez, Anthony ^a   Colvin, Richard ^a   Fuller, John ^a   Jones, Adriana K ^a   Li, Cindy ^a   Lopez, Sara ^a   Metzger, Louis E ^a,c   Mostafavi, Mina ^a   Prathapam, Ramadevi ^a   Rasper, Dita ^a   Reck, Folkert ^a   Ruzin, Alexey ^a,d   Shaul, Jacob ^a   Shen, Xiaoyu ^a   Simmons, Robert L ^a   Skewes Cox, Peter ^a   Takeoka, Kenneth T ^a   Tamrakar, Pramila ^a   Uehara, Tsuyoshi ^a   Wei, Jun Rong ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c Synvitrobio Inc ^*  (United States)

^d MEDIMMUNE   (United States)

Author keywords

Beta lactamases; Drug resistance mechanisms; Enterobacteriaceae; LYS228; Mechanisms of action; Monobactam

Indexed keywords

BETA LACTAMASE; LYS 228; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN BBINDING PROTEIN 3; PENICILLIN BINDING PROTEIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZTREONAM;

ACYLATION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CELL DIVISION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG MECHANISM; DRUG PROTEIN BINDING; ESCHERICHIA COLI; GENE MUTATION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; AZTREONAM; BETA-LACTAMASES; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MONOBACTAMS; MUTATION;

EID: 85053924969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/aac.01200-18     Document Type: Article

References (61)

1. Watkins RR, Bonomo RA. 2016. Overview: Global and local impact of antibiotic resistance. Infect Dis Clin North Am 30:313-322. https://doi .org/10.1016/j.idc.2016.02.001.
2. East SP, Silver LL. 2013. Multitarget ligands in antibacterial research: Progress and opportunities. Expert Opin Drug Discov 8:143-156. https://doi.org/10.1517/17460441.2013.743991.
3. O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. 2015. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother 59:289 -298. https://doi .org/10.1128/AAC.03774-14.
4. Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. 2011. Discovery research: The scientific challenge of finding new antibiotics. J Antimicrob Chemother 66:1941-1944. https://doi.org/10.1093/jac/dkr262.
5. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Olafsdottir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. 2016. Alternatives to antibiotics- A pipeline portfolio review. Lancet Infect Dis 16:239 -251. https://doi.org/10.1016/S1473-3099(15)00466-1.
6. Bush K. 2013. Proliferation and significance of clinically relevant betalactamases. Ann N Y Acad Sci 1277:84-90. https://doi.org/10.1111/nyas .12023.
7. Queenan AM, Bush K. 2007. Carbapenemases: The versatile betalactamases. Clin Microbiol Rev 20:440-458. https://doi.org/10.1128/CMR .00001-07.
8. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New beta-lactamase inhibitors: A therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-1846. https://doi.org/10.1128/AAC.00826-13.
9. Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study. Lancet Infect Dis 11:355-362. https://doi.org/10.1016/S1473-3099(11)70059-7.
10. Felici A, Amicosante G. 1995. Kinetic analysis of extension of substrate specificity with Xanthomonas maltophilia, Aeromonas hydrophila, and Bacillus cereus metallo-beta-lactamases. Antimicrob Agents Chemother 39:192-199. https://doi.org/10.1128/AAC.39.1.192.
11. Felici A, Amicosante G, Oratore A, Strom R, Ledent P, Joris B, Fanuel L, Frere JM. 1993. An overview of the kinetic parameters of class B beta-lactamases. Biochem J 291(Part 1):151-155. https://doi.org/10 .1042/bj2910151.
12. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. 2017. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 61:e00472-17. https://doi.org/10.1128/AAC.00472-17.
13. Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, Colvin R, Dean CR, Fekete A, Gong W, Growcott E, Guo H, Jones AK, Li C, Li F, Lin X, Lindvall M, Lopez S, McKenney D, Metzger L, Moser HE, Prathapam R, Rasper D, Rudewicz P, Sethuraman V, Shen X, Shaul J, Simmons RL, Tashiro K, Tang D, Tjandra M, Turner N, Uehara T, Vitt C, Whitebread S, Yifru A, Zang X, Zhu Q. 2018. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae-identification of LYS228. Bioorg Med Chem Lett 28:748 -755. https://doi.org/10.1016/j.bmcl.2018.01.006.
14. Blais J, Lopez S, Li C, Ruzin A, Ranjitkar S, Dean CR, Leeds JA, Casarez A, Simmons RL, Reck F. 23 July 2018. In vitro activity of LYS228, a novel monobactam antibiotic, against multidrug-resistant Enterobacteriaceae. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.00552-18.
15. Georgopapadakou NH, Smith SA, Sykes RB. 1982. Mode of action of azthreonam. Antimicrob Agents Chemother 21:950 -956. https://doi.org/10.1128/AAC.21.6.950.
16. Nonejuie P, Burkart M, Pogliano K, Pogliano J. 2013. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc Natl Acad Sci U S A 110:16169-16174. https://doi .org/10.1073/pnas.1311066110.
17. Pogliano J, Pogliano K, Weiss DS, Losick R, Beckwith J. 1997. Inactivation of FtsI inhibits constriction of the FtsZ cytokinetic ring and delays the assembly of FtsZ rings at potential division sites. Proc Natl Acad Sci U S A 94:559 -564. https://doi.org/10.1073/pnas.94.2.559.
18. Huisman O, D'Ari R, Gottesman S. 1984. Cell-division control in Escherichia coli: Specific induction of the SOS function SfiA protein is sufficient to block septation. Proc Natl Acad Sci U S A 81:4490-4494. https://doi .org/10.1073/pnas.81.14.4490.
19. Curtis NA, Orr D, Ross GW, Boulton MG. 1979. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother 16: 533-539. https://doi.org/10.1128/AAC.16.5.533.
20. Keeney D, Ruzin A, Bradford PA. 2007. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 13:1- 6. https://doi.org/10.1089/mdr.2006.9990.
21. Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA. 2008. MarAmediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 61:46 -53. https://doi.org/10.1093/jac/dkm397.
22. Ruzin A, Immermann FW, Bradford PA. 2008. Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 52:3430 -3432. https://doi.org/10.1128/AAC.00591-08.
23. Ruzin A, Keeney D, Bradford PA. 2005. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 49:791-793. https://doi.org/10.1128/AAC.49.2 .791-793.2005.
24. Baranova N, Nikaido H. 2002. The BaeSR two-component regulatory system activates transcription of the yegMNOB (mdtABCD) transporter gene cluster in Escherichia coli and increases its resistance to novobiocin and deoxycholate. J Bacteriol 184:4168-4176. https://doi.org/10.1128/JB.184.15.4168-4176.2002.
25. Leblanc SK, Oates CW, Raivio TL. 2011. Characterization of the induction and cellular role of the BaeSR two-component envelope stress response of Escherichia coli. J Bacteriol 193:3367-3375. https://doi.org/10.1128/JB .01534-10.
26. Hirakawa H, Nishino K, Yamada J, Hirata T, Yamaguchi A. 2003. Beta-lactam resistance modulated by the overexpression of response regulators of two-component signal transduction systems in Escherichia coli. J Antimicrob Chemother 52:576 -582. https://doi.org/10 .1093/jac/dkg406.
27. Kobayashi N, Tamura N, van Veen HW, Yamaguchi A, Murakami S. 2014. Beta-lactam selectivity of multidrug transporters AcrB and AcrD resides in the proximal binding pocket. J Biol Chem 289:10680-10690. https://doi.org/10.1074/jbc.M114.547794.
28. De Majumdar S, Yu J, Spencer J, Tikhonova IG, Schneiders T. 2014. Molecular basis of non-mutational derepression of ramA in Klebsiella pneumoniae. J Antimicrob Chemother 69:2681-2689. https://doi.org/10 .1093/jac/dku203.
29. Bratu S, Landman D, George A, Salvani J, Quale J. 2009. Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J Antimicrob Chemother 64:278 -283. https://doi.org/10.1093/jac/dkp186.
30. Hentschke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. 2010. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob Agents Chemother 54: 2720-2723. https://doi.org/10.1128/AAC.00085-10.
31. Rosenblum R, Khan E, Gonzalez G, Hasan R, Schneiders T. 2011. Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae. Int J Antimicrob Agents 38:39-45. https://doi .org/10.1016/j.ijantimicag.2011.02.012.
32. Jimenez-Castellanos JC, Wan Ahmad Kamil WN, Cheung CH, Tobin MS, Brown J, Isaac SG, Heesom KJ, Schneiders T, Avison MB. 2016. Comparative effects of overproducing the AraC-type transcriptional regulators MarA, SoxS, RarA and RamA on antimicrobial drug susceptibility in Klebsiella pneumoniae. J Antimicrob Chemother 71:1820 -1825. https://doi.org/10.1093/jac/dkw088.
33. Jimenez-Castellanos JC, Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Schneiders T, Heesom KJ, Avison MB. 2018. Envelope proteome changes driven by RamA overproduction in Klebsiella pneumoniae that enhance acquired beta-lactam resistance. J Antimicrob Chemother 73:88 -94. https://doi.org/10.1093/jac/dkx345.
34. Nishino K, Nikaido E, Yamaguchi A. 2007. Regulation of multidrug efflux systems involved in multidrug and metal resistance of Salmonella enterica serovar Typhimurium. J Bacteriol 189:9066 -9075. https://doi.org/10.1128/JB.01045-07.
35. Lin MF, Lin YY, Yeh HW, Lan CY. 2014. Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility. BMC Microbiol 14:119. https://doi.org/10.1186/1471-2180-14-119.
36. Broberg CA, Wu W, Cavalcoli JD, Miller VL, Bachman MA. 2014. Complete genome sequence of Klebsiella pneumoniae strain ATCC 43816 KPPR1, a rifampin-resistant mutant commonly used in animal, genetic, and molecular biology studies. Genome Announc 2:e00924-14. https://doi.org/10.1128/genomeA.00924-14.
37. Raivio TL, Leblanc SK, Price NL. 2013. The Escherichia coli Cpx envelope stress response regulates genes of diverse function that impact antibiotic resistance and membrane integrity. J Bacteriol 195:2755-2767. https://doi.org/10.1128/JB.00105-13.
38. Delhaye A, Collet JF, Laloux G. 2016. Fine-tuning of the Cpx envelope stress response is required for cell wall homeostasis in Escherichia coli. mBio 7:e00047-16. https://doi.org/10.1128/mBio.00047-16.
39. Srinivasan VB, Vaidyanathan V, Mondal A, Rajamohan G. 2012. Role of the two component signal transduction system CpxAR in conferring cefepime and chloramphenicol resistance in Klebsiella pneumoniae NTUH-K2044. PLoS One 7:e33777. https://doi.org/10.1371/journal .pone.0033777.
40. Tian ZX, Yi XX, Cho A, O'Gara F, Wang YP. 2016. CpxR activates MexAB-OprM efflux pump expression and enhances antibiotic resistance in both laboratory and clinical nalB-type isolates of Pseudomonas aeruginosa. PLoS Pathog 12:e1005932. https://doi.org/10.1371/journal.ppat.1005932.
41. Hu WS, Chen HW, Zhang RY, Huang CY, Shen CF. 2011. The expression levels of outer membrane proteins STM1530 and OmpD, which are influenced by the CpxAR and BaeSR two-component systems, play important roles in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 55:3829 -3837. https://doi.org/10.1128/AAC.00216-11.
42. Keller R, Arioz C, Hansmeier N, Stenberg-Bruzell F, Burstedt M, Vikstrom D, Kelly A, Wieslander A, Daley DO, Hunke S. 2015. The Escherichia coli envelope stress sensor CpxA responds to changes in lipid bilayer properties. Biochemistry 54:3670 -3676. https://doi.org/10.1021/acs.biochem .5b00242.
43. De la Cruz MA, Perez-Morales D, Palacios IJ, Fernandez-Mora M, Calva E, Bustamante VH. 2015. The two-component system CpxR/A represses the expression of Salmonella virulence genes by affecting the stability of the transcriptional regulator HilD. Front Microbiol 6:807. https://doi.org/10 .3389/fmicb.2015.00807.
44. Srinivasan VB, Rajamohan G. 2013. KpnEF, a new member of the Klebsiella pneumoniae cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resistance. Antimicrob Agents Chemother 57:4449-4462. https://doi.org/10.1128/AAC .02284-12.
45. Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S, Rezayat A, Garudathri J, Harrison JJ, Harwood RA, Penewit K, Waalkes A, Singh PK, Salipante SJ. 2017. Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa. mBio 8:e00517-17. https://doi.org/10.1128/mBio.00517-17.
46. Yakhnina AA, McManus HR, Bernhardt TG. 2015. The cell wall amidase AmiB is essential for Pseudomonas aeruginosa cell division, drug resistance and viability. Mol Microbiol 97:957-973. https://doi.org/10.1111/mmi.13077.
47. Alm RA, Johnstone MR, Lahiri SD. 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: Role of a novel insertion in PBP3. J Antimicrob Chemother 70:1420 -1428. https://doi.org/10.1093/jac/dku568.
48. Adler M, Anjum M, Andersson DI, Sandegren L. 2016. Combinations of mutations in envZ, ftsI, mrdA, acrB and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother 71: 1188-1198. https://doi.org/10.1093/jac/dkv475.
49. Cai SJ, Inouye M. 2002. EnvZ-OmpR interaction and osmoregulation in Escherichia coli. J Biol Chem 277:24155-24161. https://doi.org/10.1074/jbc.M110715200.
50. Ma C, Sim S, Shi W, Du L, Xing D, Zhang Y. 2010. Energy production genes sucB and ubiF are involved in persister survival and tolerance to multiple antibiotics and stresses in Escherichia coli. FEMS Microbiol Lett 303:33- 40. https://doi.org/10.1111/j.1574-6968.2009.01857.x.
51. Asli A, Brouillette E, Krause KM, Nichols WW, Malouin F. 2016. Distinctive binding of avibactam to penicillin-binding proteins of Gram-negative and Gram-positive bacteria. Antimicrob Agents Chemother 60:752-756. https://doi.org/10.1128/AAC.02102-15.
52. Livermore DM, Warner M, Mushtaq S, Woodford N. 2016. Interactions of OP0595, a novel triple-action diazabicyclooctane, with betalactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 60:554 -560. https://doi.org/10.1128/AAC .02184-15.
53. Jones AK, Ranjitkar S, Li C, Lopez S, Blais J, Reck F, Dean CR. 30 July 2018. Impact of inducible blaDHA-1 on susceptibility of Klebsiella pneumoniae clinical isolates to LYS228 and identification of chromosomal mpl and ampD mutations mediating upregulation of plasmidborne blaDHA-1 expression. Antimicrob Agents Chemother https://doi .org/10.1128/AAC.01202-18.
54. Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, Owens RJ, Ren J. 2011. Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: Comparison of native and antibiotic-bound forms. J Mol Biol 405:173-184. https://doi.org/10.1016/j.jmb.2010.10 .024.
55. di Guilmi AM, Mouz N, Martin L, Hoskins J, Jaskunas SR, Dideberg O, Vernet T. 1999. Glycosyltransferase domain of penicillin-binding protein 2a from Streptococcus pneumoniae is membrane associated. J Bacteriol 181:2773-2781.
56. Zhao G, Meier TI, Kahl SD, Gee KR, Blaszczak LC. 1999. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillinbinding proteins. Antimicrob Agents Chemother 43:1124-1128.
57. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671- 675. https://doi.org/10 .1038/nmeth.2089.
58. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically. Approved standard, 10th ed, supplement M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
59. Horton RM, Cai ZL, Ho SN, Pease LR. 1990. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. Biotechniques 8:528 -535.
60. Prilipov A, Phale PS, Van Gelder P, Rosenbusch JP, Koebnik R. 1998. Coupling site-directed mutagenesis with high-level expression: Large scale production of mutant porins from E. coli. FEMS Microbiol Lett 163:65-72. https://doi.org/10.1111/j.1574-6968.1998.tb13027.x.
61. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 53: 60-67. https://doi.org/10.1093/cid/cir202.